CareFusion — Merger or Acquisition (October 2014)
14 slides from CareFusion's merger presentation, Oct 6, 2014
Slide 1: A Leader in Medication Management and Patient Safety
Exhibit 99.2 A Leader in Medication Management and Patient Safety October 6th, 2014
Slide 2: Important Information for Investors
IMPORTANT INFORMATION FOR INVESTORS In connection with the proposed transaction, BD will file with the SEC a registration statement on Form S–4 that will constitute a prospectus of BD and include a proxy statement of CareFusion. BD and CareFusion also plan to file other relevant documents with the S
Slide 3: Forward-looking statements
This slide presentation contains certain estimates and other forward-looking statements (as defined under Federal securities laws). Forward looking statements generally are accompanied by words such as “will”, "expect", "outlook" or other similar words, phrases or expressions. These forward-looking
Slide 4: Speakers on Today's Call
Speakers on Today’s Call Vince Forlenza Kieran Gallahue Christopher Reidy Chairman, CEO & Chairman & CEO CFO and EVP, President CareFusion Corp. Administration Becton, Dickinson & Co. Becton, Dickinson & Co. 1 4
Slide 5: Compelling Strategic Transaction
Compelling Strategic Transaction Accelerates BD’s strategy to A Leader in Medication deliver complete solutions that Management and meet evolving industry needs Patient Safety Builds scale and depth to $12 billion in combined create unique growth annualized revenues opportunities, leveraging BD’s in
Slide 6: Key Highlights
Key Highlights BD is a company with strong values and a track record of success Announcement accelerates CareFusion’s plans to build greater scale New growth opportunities for products in emerging markets and expands global reach by leveraging BD’s international infrastructure Offers a complete suit
Slide 7: Accelerates BD's Strategy
Accelerates BD’s Strategy Today Becoming a provider of complete healthcare solutions Moved into near adjacencies Accelerated revenue growth 2013 to 2014 Delivered higher quality of earnings New products as a percentage of sales increased from 8% to 15% Built targeted M&A capabilities Emerging market
Slide 8: Builds Scale and Depth in Medication Management
Builds Scale and Depth in Medication Management More than doubles BD Medical’s Becomes a global leader in medication addressable opportunity from management, with a leading informatics about $8B to $16B platform across value chain Prepare Dispense Administer Monitor BD CareFusion BD+CareFusion New/S
Slide 9: Leveraging BD's International Footprint
Leveraging BD’s International Footprint Opportunity for Growth Emerging Developed Emerging 5% 20% Leverage BD’s investments in Asia 75% U.S. Pacific, Latin America, EMEA Accelerate uptake of CareFusion products and solutions tailored to these markets Developed Emerging Optimize end-to-end medication
Slide 10: Transaction Overview
Transaction Overview Total consideration of $12.2 billion in cash and BD stock BD to assume ~$2.0 billion of CareFusion debt and $1.8 billion of cash Transaction Represents per share consideration for CareFusion shareholders of: Terms $49.00 in cash 0.0777 shares of new BD shares CareFusion sharehol
Slide 11: Creates Meaningful Value for Shareholders
Creates Meaningful Value for Shareholders Stronger platform for diversified growth Growth Leverage BD’s strong international presence to accelerate growth of CareFusion products Consistent with BD’s long term revenue growth aspirations Approximately $250 million of cost synergies Synergies Fully rea
Slide 12: Detailed Execution Plan for a Seamless Integration
Detailed Execution Plan for a Seamless Integration Designated integration planning team led by BD Chief Operating Officer Bill Kozy Team includes senior members of both organizations by geography, function and business unit Confident in ability to achieve identified cost synergies CareFusion busines
Slide 13: Compelling Strategic Transaction
Compelling Strategic Transaction A Leader in Medication Management and Patient Safety $12 billion in combined annualized revenues 46,000 employees worldwide Presence in almost every country around the world Significantly increases BD’s addressable opportunity 13
Slide 14: Trademark notice
BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. 14